Valuation: Cybin

Market Cap 1.24B 870M 773M 723M 659M 83.78B 1.26B 8.74B 3.38B 42.67B 3.27B 3.2B 137B P/E 2027 *
-4.57x
P/E 2028 * -5.54x
Enterprise Value 757M 531M 472M 441M 402M 51.17B 768M 5.34B 2.07B 26.06B 2B 1.95B 83.7B EV / Sales 2027 *
-
EV / Sales 2028 * 60.4x
Free-Float
85.98%
Yield 2027 *
-
Yield 2028 * -
1 day-3.09%
1 week-5.40%
Current month-3.09%
1 month+2.67%
3 months+89.65%
6 months+138.68%
Current year+45.60%
1 week 11.63
Extreme 11.63
12.96
1 month 11.39
Extreme 11.39
15.15
Current year 3.76
Extreme 3.76
15.15
1 year 3.76
Extreme 3.76
15.15
3 years 3.76
Extreme 3.76
28.04
5 years 3.76
Extreme 3.76
89.49
10 years 3.76
Extreme 3.76
128.44
Manager TitleAgeSince
Chief Operating Officer 37 13/10/2016
Chief Executive Officer 53 03/08/2026
Chief Executive Officer 51 02/09/2025
Director TitleAgeSince
Chairman 51 05/11/2020
Director/Board Member 37 13/10/2016
Director/Board Member 65 05/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
21/9/26 Buy

Chief Executive Officer

100,000 0.1613%
21/9/26 Buy

Chief Executive Officer

100,000 0.1613%
17/9/26 Other

Chief Executive Officer

1,426,902 2.3020%
Change 5-day change 1-year change 3-year change Capi.($)
-3.09%-5.40%+99.16%-41.02% 870M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.90%-1.33%+24.70%+78.59% 59.26B
+1.41%-0.42%+4.50%+34.79% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -0.73%-1.01%+57.51%+134.63% 39.33B
Weighted average by Cap. +0.09%-0.33%+58.17%+145.44%

Financials

2027 *2028 *
Net sales - 11.07M 7.77M 6.9M 6.45M 5.88M 748M 11.22M 78.04M 30.21M 381M 29.16M 28.53M 1.22B
Net income -261M -183M -163M -152M -139M -17.66B -265M -1.84B -713M -8.99B -689M -674M -28.89B -262M -184M -163M -153M -139M -17.68B -265M -1.84B -714M -9B -689M -674M -28.92B
Net Debt -483M -339M -301M -281M -256M -32.61B -489M -3.4B -1.32B -16.61B -1.27B -1.24B -53.34B -571M -401M -356M -333M -303M -38.58B -579M -4.03B -1.56B -19.65B -1.5B -1.47B -63.11B
Logo Cybin
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
100
Date Price Change Volume
01/10/26 US$11.91 -3.09% 1,328,306
30/09/26 US$12.29 -3.23% 823,389
29/09/26 US$12.70 +0.87% 972,657
28/09/26 US$12.59 -0.16% 986,597
25/09/26 US$12.61 +0.16% 805,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
16.97CAD
Average target price
56.76CAD
Spread / Average Target
+234.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HELP Stock